Copyright ©The Author(s) 2018.
World J Gastrointest Oncol. Aug 15, 2018; 10(8): 202-210
Published online Aug 15, 2018. doi: 10.4251/wjgo.v10.i8.202
Table 1 Summary of existing studies evaluating the efficacy of anti-stromal agents in the treatment of metastatic pancreatic cancer
AgentTargetTreatment arm (s)Type of studyNational clinical trial numberStatusResults
ParicalcitolVitamin D metabolic pathwayGemcitabine and nab-paclitaxel plus paricalcitol or placeboPhase I/IINCT03520790Recruiting
Nab-paclitaxel, cisplatin and gemcitabine plus paricalcitolPhase IINCT03415854Recruiting
Nivolimumab1, nab-paclitaxel, cisplatin, and gemcitabine plus paricalcitolPhase IINCT02754726Recruiting
Pembrolizumab1 plus paricalcitol or placeboPhase IINCT03331562Recruiting
All trans retinoic acidPancreatic stellate cellsGemcitabine and nab-paclitaxel plus all trans retinoic acidPhase INCT03307148Recruiting
VismodegibHedgehog signalingGemcitabine plus vismodegib or placeboPhase I/IINCT0106422CompletedVismodegib did not improve ORR, PFS and OS
IPI-926Hedgehog signalingFOLFIRINOX plus IPI-926Phase INCT01383538CompletedThe combination treatment was safe but IP-926 was not beneficial
Gemcitabine plus IPI-926 or placeboPhase I/IINCT01130142CompletedThe combination treatment was well tolerated, and showed promising activity
PEGPH20Hyaluronic acidGemcitabine and nab-paclitaxel plus PEGPH20 vs chemotherapy alonePhase IINCT01839487CompletedPEGPH20 significantly improved PFS, especially in patients having tumors with high-level hyaluronic acid
Gemcitabine and nab-paclitaxel plus PEGPH20 or placebo2Phase IIINCT02715804Recruiting
Modified FOLFIRINOX plus PEGPH20 vs chemotherapy alonePhase I/IINCT01959139ClosedPEGPH20 was found to have a detrimental effect on OS